- Report
- June 2024
- 120 Pages
North America
From €3492EUR$3,869USD£3,034GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3492EUR$3,869USD£3,034GBP
- Report
- April 2024
- 140 Pages
Global
From €4466EUR$4,949USD£3,880GBP
- Report
- August 2024
- 140 Pages
Global
From €2674EUR$2,963USD£2,323GBP
€3565EUR$3,950USD£3,097GBP
- Report
- July 2024
- 112 Pages
Europe
From €3113EUR$3,450USD£2,705GBP
- Report
- April 2024
- 101 Pages
Europe
From €3113EUR$3,450USD£2,705GBP
- Report
- November 2023
- 185 Pages
Global
From €4016EUR$4,450USD£3,489GBP
- Report
- September 2023
- 216 Pages
Global
From €4016EUR$4,450USD£3,489GBP
- Report
- February 2024
- 234 Pages
Global
€4508EUR$4,995USD£3,916GBP
- Report
- January 2024
Global
From €3249EUR$3,600USD£2,823GBP
- Report
- February 2025
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- April 2023
- 91 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- November 2025
- 132 Pages
Global
From €857EUR$950USD£745GBP

The Viral Vector Manufacturing market is a subset of the genomics industry that focuses on the production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, cystic fibrosis, and hemophilia.
The Viral Vector Manufacturing market is highly competitive, with a number of companies offering a range of services. These services include vector design, vector production, and vector characterization. Companies also provide custom services to meet the specific needs of their customers.
Some of the major players in the Viral Vector Manufacturing market include Lonza, Thermo Fisher Scientific, Merck KGaA, and Oxford BioMedica. These companies offer a range of services, from vector design to vector production and characterization. Show Less Read more